Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells

Ibrutinib (PCI-32765) is an irreversible dual Btk/Itk inhibitor shown to be effective in treating several B cell malignancies. However, limited studies have been conducted to study the effect of this drug on myeloid cell function. Hence, we studied the effect of ibrutinib treatment on TLR-4 mediated...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Natarajan, Gayathri, Terrazas, Cesar, Oghumu, Steve, Varikuti, Sanjay, Dubovsky, Jason A, Byrd, John C, Satoskar, Abhay R
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2015
Témata:
Brief Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4760285/
https://ncbi.nlm.nih.gov/pubmed/26942065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1057385
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky